Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma.

Trial Profile

Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Cisplatin (Primary) ; Etoposide (Primary) ; Gemcitabine (Primary) ; Methylprednisolone (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jun 2013 Planned end date changed from 1 Jan 2015 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 03 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Additional location (Canada) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top